# IGM Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/igm-biosciences

- Industry: Biotechnology
- Headquarters: Mountain View, US
- Website: www.igmbio.com
- Total disclosed funding: $102M
- Latest round: Series C (Jul 8, 2019)
- Investors on record: 5

## About

IGM Biosciences, Inc. focuses on developing innovative antibody therapeutics designed to treat autoimmune and inflammatory diseases by harnessing the unique binding properties of engineered IgM antibodies.Founded in 2010 and headquartered in Mountain View, US, IGM Biosciences, Inc. specializes in creating engineered therapeutic IgM antibodies. The company has undergone significant funding rounds, including a notable Private Placement of USD 84.7 mn in June 2023, raising a total of USD 84.7 mn to date. Fred Schwarzer serves as the CEO, leading the organization through various strategic initiatives. IGM has closed 8 deals since inception, with the most recent deal occurring on June 22, 2023.IGM Biosciences specializes in developing a novel class of antibody therapeutics aimed at treating autoimmune and inflammatory diseases. Their core offerings are engineered therapeutic IgM antibodies, which leverage superior binding capabilities compared to conventional IgG antibodies. These antibodies are being designed to provide new treatment options for patients with autoimmune disorders. The company’s R&D efforts focus on enhancing the natural properties of IgM antibodies to ensure scalable production, aiming to meet the significant demand for innovative therapies in North America and Europe.In the most recent year, IGM Biosciences reported a revenue of USD 2.68 mn for 2024, along with an EBITDA of USD -199.47 mn. The company's revenue primarily stems from partnerships and collaborations with pharmaceutical firms and research institutions, structured through licensing agreements and collaborative research initiatives.Following its most recent funding round on June 22, 2023, IGM Biosciences plans to allocate the USD 84.7 mn raised to advance its proprietary oncology pipeline, particularly the lead program involving a CD20 x CD3 bispecific antibody. The company is also targeting the expansion of its market reach into new geographic areas, with an emphasis on enhancing its presence in North America and Europe, as it prepares for the launch of upcoming products designed to address unmet medical needs in the field of immunology.

## Funding rounds

- Series C, Jul 8, 2019, $102M — Vivo Capital, Redmile Group, Janus Henderson Investors, Topsoe A/S, Baker Brothers Advisors LLC

## Investors

- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C
- Janus Henderson Investors — Series C
- Topsoe A/S — Series C
- Baker Brothers Advisors LLC — Series C